GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 2

Terminated

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: Pembrolizumab
Drug: Dostarlimab
Drug: Chemotherapy

First Posted Date: 2020-10-09

Last Posted Date: 2025-04-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 243

Registration Number: NCT04581824

Locations: 🇨🇳
GSK Investigational Site, Taipei, Taiwan

A Study to Assess the Local Cutaneous and Ocular Tolerance of Three Developmental Facial Skin-care Formulations.

Not Applicable

Completed

Conditions: Skin Care

Interventions: Other: Cream
Other: Serum
Other: Lotion

First Posted Date: 2020-09-21

Last Posted Date: 2022-04-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 150

Registration Number: NCT04557371

Locations: 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany

Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan

Active, not recruiting

Conditions: Churg-Strauss Syndrome
Eosinophilic Granulomatosis With Polyangiitis

First Posted Date: 2020-09-16

Last Posted Date: 2022-09-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 120

Registration Number: NCT04551989

Locations: 🇯🇵
GSK Investigational Site, Yamaguchi, Japan

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

Phase 3

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin

First Posted Date: 2020-09-16

Last Posted Date: 2023-12-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT04549363

Locations: 🇺🇸
GSK Investigational Site, Chapel Hill, North Carolina, United States

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

Phase 1

Recruiting

Conditions: Neoplasms

Interventions: Drug: Dostarlimab
Drug: Niraparib (Tablet for oral suspension)
Drug: Niraparib (Tablet)

First Posted Date: 2020-09-10

Last Posted Date: 2025-04-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 116

Registration Number: NCT04544995

Locations: 🇬🇧
GSK Investigational Site, Sutton, United Kingdom

A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B

Phase 2

Completed

Conditions: Hepatitis B

Interventions: Drug: GSK3228836
Drug: Nucleos(t)ide therapy

First Posted Date: 2020-09-10

Last Posted Date: 2024-12-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT04544956

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers

Phase 4

Completed

Conditions: Diphtheria

Interventions: Biological: DTPa-HBV-IPV/Hib
Biological: DTaP5-HBV-IPV-Hib
Biological: Pneumococcal 13-valent conjugate vaccine

First Posted Date: 2020-09-01

Last Posted Date: 2024-08-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 500

Registration Number: NCT04535037

Locations: 🇪🇸
GSK Investigational Site, Sevilla, Spain

Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants

Phase 1

Completed

Conditions: Leishmaniasis

Interventions: Drug: GSK3494245
Drug: Placebo

First Posted Date: 2020-08-07

Last Posted Date: 2024-02-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 59

Registration Number: NCT04504435

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

Phase 3

Completed

Conditions: Infections, Meningococcal

Interventions: Combination Product: rMenB+OMV NZ vaccine
Combination Product: MenABCWY-1
Combination Product: MenABCWY-3
Biological: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Combination Product: MenABCWY-2
Combination Product: Placebo